Evidence map›Paper›PMID 40320701›Full record

Trial reportThe Prostate2025

Impact of Concomitant Hormone Therapy on the Diagnostic Performance of

Lawrence Saperstein, Steven P Rowe, Michael A Gorin, Kenneth J Pienta, Barry A Siegel, Michael J Morris, Saradha Baskaran, Nancy Stambler, Vincent A DiPippo, Bela S Denes

Abstract readClinical Trial, Phase IIClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Prostate, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lawrence SapersteinDepartment of Radiology and Biomedical Imaging, Yale School of Medicine, Connecticut, USA.
Steven P RoweDepartment of Radiology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.ORCID 0000-0003-2897-4694
Michael A GorinMilton and Carroll Petrie Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Kenneth J PientaDepartment of Oncology, Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Barry A SiegelMallinckrodt Institute of Radiology and Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Michael J MorrisGenitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Saradha BaskaranLantheus, Bedford, Massachusetts, USA.
Nancy StamblerLantheus, Bedford, Massachusetts, USA.
Vincent A DiPippoLantheus, Bedford, Massachusetts, USA.
Bela S DenesLantheus, Bedford, Massachusetts, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748This study was supported by Lantheus.
6 · The paper itself

Abstract

backgroundThis study investigates the impact of hormone therapy (HT) on the diagnostic performance of

methods

resultsIn OSPREY cohort B, 34.4% of patients (32/93) were on at least one concomitant HT with a median exposure duration of 15.5 months. The median baseline PSA and testosterone levels for patients on concurrent HT (n = 32) were 31.6 ng/mL and 9 ng/dL, respectively. For patients not on concurrent therapy (n = 61), median PSA and testosterone levels were 6.1 ng/mL and 317.35 ng/dL, respectively. The median sensitivity of

conclusionsThe diagnostic performance of

Indexed as

Positron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overCohort StudiesFluorine RadioisotopesHumansMaleMiddle AgedNeoplasm Recurrence, LocalProstate-Specific AntigenTestosteroneFluorine RadioisotopesProstate-Specific AntigenTestosterone18F‐piflufolastathormone therapyprostate cancerprostate‐specific membrane antigenPSMA‐PET/CT

Identifiers

PMID40320701
PMCPMC12211537

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.